Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.92 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.92 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.92 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | BLM | P54132 | 2/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988430 | 1.00 | PI4KA (0.92) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL8712264 | 0.96 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL896095 | 0.96 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL30352942 | 0.96 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL31569297 | 0.84 | CYP2C19 (0.74) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL4572213 | 0.84 | CYP2C19 (0.74) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL1324553 | 0.83 | CYP2C19 (0.72) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL115599 | 0.83 | CYP2C19 (0.68) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL219612 | 0.83 | CYP2C19 (0.68) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL2876046 | 0.83 | CYP2C19 (0.68) | PI4KAPI4K2BPI4K2API4KBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324765-A | Synthesis method of PI3K inhibitor Du Weili sibutra | 江苏海洋大学 | 2024-07-12 | — | — | CN | claimed |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2025-05-29 | — | — | US | disclosed |
| CN-118324765-A | Synthesis method of PI3K inhibitor Du Weili sibutra | 江苏海洋大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-118324765-A | Synthesis method of PI3K inhibitor Du Weili sibutra | 江苏海洋大学 | 2024-07-12 | — | — | CN | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20220372048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2022-11-24 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220265637-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2022-08-25 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009088986-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009088990-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20020061509-A1 | Screening assay for the identification of agents which alter expression of PTH-rP | OSTEO SCREEN | 2002-05-23 | — | — | US | disclosed |
| US-5914233-A | TRANSFORMATION OF TUMOR CELL LINES WITH EXPRESSION VECTOR ENCODING A PROMOTER REGION OF PARATHYROID HORMONE (PTH) LINKED TO REPORTER GENE ENCODING ASSAYABLE CULTURE PRODUCT | OSTEO SCREEN (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1998007844-A2 | SCREENING ASSAY FOR THE IDENTIFICATION OF AGENTS WHICH ALTER EXPRESSION OF PTH-rP | OSTEOSCREEN (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265637-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PI4KA 8/4885PI4K2B 30/4885PI4K2A 22/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PI4KA 8/4885PI4K2B 30/4885PI4K2A 22/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | PI4KA 8/4885PI4K2B 28/4885PI4K2A 24/4885 |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PTEN, PIK3C2A, PIK3CA | PI4KA 41/4885PI4K2B 42/4885PI4K2A 62/4885 |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PI4KA 8/4885PI4K2B 30/4885PI4K2A 22/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | PI4KA 4208/4885PI4K2B 4434/4885PI4K2A 4199/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | PI4KA 4208/4885PI4K2B 4434/4885PI4K2A 4199/4885 |
| US-20220372048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PI4KA 11/4885PI4K2B 45/4885PI4K2A 31/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | PI4KA 10/4885PI4K2B 43/4885PI4K2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.